Pulmonary complications after cardiac surgery is a topic of significant interest to cardiac surgeons and anesthesiologists. Despite its relevance and importance to clinical practice, our understanding of its pathophysiology remains woefully incomplete. Multiple plausible hypotheses were advanced, offering many interesting insights, but their empiric confirmation remains elusive. Thus, we (again!) attempt to speculate on the ever-present dichotomy between the theoretical expectations of pulmonary protective ventilation during cardiopulmonary bypass (CPB) and the empiric evidence for its benefits (or lack thereof). Fiorentino et al 1 present the readers with the results of their randomized controlled trial relating the effects of low frequency ventilation (LFV) on the pulmonary inflammatory pathways and indices of gas exchange. To their surprise, they observed no significant differences in outcomes between the cohort of interest (patients ventilated with air during CPB at 6 to 8 mL/ kg, 5 breaths/minute, and zero end-expiratory pressure) and the controls (patients whose lungs were disconnected from the breathing circuit and remained collapsed for the duration of CPB). Furthermore, the tissue expression of IL-6 and IL-1B genes favored the controls, and the need for hemodynamic support was higher in the LFV group. While the study was neither powered nor designed to test the associations between the biochemical markers and the clinical outcomes, the authors could not escape the conclusion that, contrary to their expectations, LFV during CPB did not demonstrate the desired anti-inflammatory effects.The authors are to be saluted for the meticulously executed research and integrity in reporting the results that clearly contradict their previously published experimental results. 2 But how are we to view these newly presented data that seem to upend the theoretical foundations of clinical gestalt and practice?We believe that the study is important is several aspects. As the experimental design involved a conventional conduct of CPB with complete diversion of venous blood away from the pulmonary artery into the CPB circuit, their findings may point to the possibility of harm associated with alveolar ventilation in the absence of pulmonary perfusion. Local and regional inflammatory pathways, activated within the ischemic alveolar unit and potentiated by the subsequent ischemiareperfusion injury, could contribute to pulmonary inflammation as significantly as alveolar collapse and atelectasis. 3 Seen in this light, it is easy to imagine that the uptick in tissue inflammatory expression observed in the LFV group may reflect further potentiation of the ischemic insult by the continuous ventilation of the nonperfused alveolar unit.Another potential consideration is the mode of on-bypass ventilation in the authors' experimental design. LFV with volumes < 8 mL/kg and zero end-expiratory pressure could be deleterious in of itself. 4 It may potentiate airway closure, promote significant regional ventilatory heterogeneity associated w...